Wilkinson, Shane M, Barron, Melissa L, O'Brien-Brown, James, Janssen, Bieneke, Stokes, Leanne ORCID: https://orcid.org/0000-0003-4013-6781, Werry, Eryn L., Chishty, Mansoor, Skarratt, Kristen K., Ong, Jennifer A., Hibbs, David E., Vugts, Danielle J., Fuller, Stephen, Windhorst, Albert D. and Kassiou, Michael (2017) Pharmacological evaluation of novel bioisosteres of an adamantanyl benzamide P2X7 receptor antagonist. ACS Chemical Neuroscience, 8 (11). 2374–2380. ISSN 1948-7193
Preview |
PDF (Accepted manuscript)
- Accepted Version
Download (559kB) | Preview |
Abstract
Adamantanyl benzamide 1 was identified as a potent P2X7R antagonist but failed to progress further due to poor metabolic stability. We describe the synthesis and SAR of a series of bioisosteres of benzamide 1 to explore improvements in the pharmacological properties of this lead. Initial efforts investigated a series of heteroaromatic bioisosteres, which demonstrated improved physicochemical properties but reduced P2X7R antagonism. Installation of bioisosteric fluorine on the adamantane bridgeheads was well tolerated and led to a series of bioisosteres with improved physicochemical properties and metabolic stability. Trifluorinated benzamide 34 demonstrated optimal physicochemical parameters, superior metabolic stability (ten times longer than lead benzamide 1), and an improved physicokinetic profile and proved effective in the presence of several known P2X7R polymorphisms.
Item Type: | Article |
---|---|
Faculty \ School: | Faculty of Science > School of Pharmacy (former - to 2024) |
UEA Research Groups: | Faculty of Science > Research Groups > Molecular and Tissue Pharmacology |
Depositing User: | Pure Connector |
Date Deposited: | 23 Nov 2017 06:05 |
Last Modified: | 25 Sep 2024 13:04 |
URI: | https://ueaeprints.uea.ac.uk/id/eprint/65543 |
DOI: | 10.1021/acschemneuro.7b00272 |
Downloads
Downloads per month over past year
Actions (login required)
View Item |